Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy
文献类型：期刊论文
| 作者 | Tan, Yan1,2; Peng, Yongbo1,2; Ai, Lili1,2; Li, Yingying1,2 ; Qu, Yi-xin1,2; Wang, Dan1,2; Su, Yuanye1,2; Deng, Tanggang1,2; Fu, Ting1,2; Zhao, Zilong1,2
|
| 刊名 | BIOCONJUGATE CHEMISTRY
 |
| 出版日期 | 2020-07-01 |
| 卷号 | 31 |
| ISSN号 | 1043-1802 |
| DOI | 10.1021/acs.bioconjchem.0c00250 |
| 通讯作者 | Wang, Xue-Qiang(wangxq@hnu.edu.cn) ; Tan, Weihong(tan@hnu.edu.cn) |
| 英文摘要 | Although the extensive clinical use of the ADC trastuzumab-DM1(T-DM1) for human epidermal growth factor receptor 2 (HER2) targeted cancer therapy, many patients who initially respond to T-DM1 treatment eventually met the insufficient efficacy issue, which is partly attributed to the decreased amount of surface HER2 caused by HER2 degradation in target cells. In our study, we have engineered a HER2 targeted DNA aptamer-DM1 conjugate (HApDC) that can maintain the homeostasis of surface HER2 on the target cancer cell. These conclusions are supported by determining the efficient internalization of HApDC into HER2 overexpressed BT474 and SKBR3 cancer cell lines and by identifying the membranal HER2 level on HApDC-treated BT474 cells. Consistent with the impressive in vitro properties of our newly developed anticancer agent, DM1 could precisely be delivered to the tumor tissue in BT474 xenografted mouse models, because of the specific recognition of aptamer. Noteworthy, HApDC exhibited excellent in vivo tumor inhibition function with much lower healthy organ toxicity, compared with the free drug, which might be explained by the persistently targeted DM1 delivery, which is attributed to the remaining HER2 levels on cells. |
| WOS关键词 | GROWTH-FACTOR RECEPTOR ; ANTIBODY ; CYCLOHEXIMIDE ; TRASTUZUMAB ; DEGRADATION ; T-DM1 ; SITE |
| 资助项目 | National Key R&D Project of China[2018YFA0902300] ; NSFC[81602499] ; NSFC[21827811] ; NSFC[91753109] ; China Scholarship Council[201906130198] ; HuXiang Young Talent Program from Hunan Province[2019RS2022] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Chemistry |
| 语种 | 英语 |
| WOS记录号 | WOS:000551492900009 |
| 出版者 | AMER CHEMICAL SOC |
| 资助机构 | National Key R&D Project of China ; NSFC ; China Scholarship Council ; HuXiang Young Talent Program from Hunan Province |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/102931]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Wang, Xue-Qiang; Tan, Weihong |
| 作者单位 | 1.Hunan Univ, Coll Biol, Coll Chem & Chem Engn, Mol Sci & Biomed Lab MBL,State Key Lab Chemo Bios, Changsha 410082, Hunan, Peoples R China 2.Hunan Univ, Aptamer Engn Ctr Hunan Prov, Changsha 410082, Hunan, Peoples R China 3.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Inst Mol Med IMM, Shanghai 200240, Peoples R China 4.Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, Shanghai 200240, Peoples R China 5.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Beijing, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Tan, Yan,Peng, Yongbo,Ai, Lili,et al. Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy[J]. BIOCONJUGATE CHEMISTRY,2020,31. |
| APA | Tan, Yan.,Peng, Yongbo.,Ai, Lili.,Li, Yingying.,Qu, Yi-xin.,...&Tan, Weihong.(2020).Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy.BIOCONJUGATE CHEMISTRY,31. |
| MLA | Tan, Yan,et al."Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy".BIOCONJUGATE CHEMISTRY 31(2020). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。